Interleukin-6 and Nerve Growth Factor Upregulation Correlates with Improved Outcome in Children with Severe Traumatic Brain Injury
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Secondary brain damage after traumatic brain injury (TBI) involves neuro-inflammatory mechanisms that are mainly dependent on the intracerebral production of cytokines. Interleukin-6 (IL-6) may have a role both in the pathogenesis of neuronal damage and in the recovery mechanisms of injured neurons through the modulation of nerve growth factor (NGF) biosynthesis. However, the relationship between IL-6 and NGF expression and the severity and outcome of TBI remains controversial. We have conducted a prospective observational clinical study to determine whether the concentration of IL-6 and NGF in the cerebrospinal fluid (CSF) of children with TBI correlates with the severity of the injury and neurologic outcome of patients. CSF samples were collected from 29 children at 2 h (time T1) and 48 h (time T2) after severe TBI, and from 31 matched controls. TBI severity was evaluated by Glasgow Coma Scale (GCS) and neurologic outcome by Glasgow Outcome Score (GOS). CSF concentrations of IL-6 and NGF were measured by immunoenzymatic assays. Early NGF concentrations (T1) correlated significantly with head injury severity, whereas no correlation was found between GCS and IL-6. Furthermore, IL-6 and NGF upregulation after injury was associated with better neurologic outcomes. Based on these findings, we posit that NGF expression is a useful marker of brain damage following severe TBI. Moreover, the early upregulation of both IL-6 and NGF, which correlates with a favorable neurologic outcome, may reflect an endogenous attempt at neuroprotection in response to the damaging biochemical and molecular cascades triggered by traumatic insult.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nerve Growth Factor Signaling, Neuroprotection, and Neural Repair
Sofroniew, M. V., Howe, C. L., & Mobley, W. C. (2001) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.24.1.1217 · Cited by 1,284
Neurologic disease induced in transgenic mice by cerebral overexpression of interleukin 6.
Campbell, I. L., Abraham, C. R., Masliah, E., Kemper, P., Inglis, J. D., Oldstone, M. B., & Mucke, L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.21.10061 · Cited by 1,006
Nerve Growth Factor Treatment After Brain Injury Prevents Neuronal Death
Kromer, L. F. (1987) · Science · doi:10.1126/science.3798108 · Cited by 932 · cited 3×
“…mechanisms of injured brain neurons (Sofroniew et al., 2001; Zhou et al., 2003) and NGF upregulation has been shown to prevent or significantly reduce severe neurological deficits, apoptosis, and brain-cell death in animal models with experimental brain injury (Kromer, 1987; Sinson et al., 1997).”
Amick, J. E., Yandora, K. A., Bell, M. J., Wisniewski, S. R., Adelson, P. D., Carcillo, J. A., Janesko, K. L., DeKosky, S. T., Carlos, T. M., Clark, R. S. B., et al. (2001) · Pediatric Critical Care Medicine · doi:10.1097/00130478-200107000-00013 · Cited by 47 · cited 1×
“Experimental and clinical studies have shown a strong correlation between secondary brain damage and neuroinflammation mechanisms due to the activation of T-cells and monocytes and the intracerebral production of cytokines (Bell et al., 1997; Amick et al., 2001; Diet-rich et al., 2004).”
Cited by
Semple, B. D., Blomgren, K., Gimlin, K., Ferriero, D. M., & Noble-Haeusslein, L. J. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.04.001 · Cited by 2,132
Traumatic Brain Injuries: Pathophysiology and Potential Therapeutic Targets
Ng, S. Y., & Lee, A. Y. W. (2019) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2019.00528 · Cited by 852
Neuroimmunology of Traumatic Brain Injury: Time for a Paradigm Shift
Jassam, Y. N., Izzy, S., Whalen, M., McGavern, D. B., & El Khoury, J. (2017) · Neuron · doi:10.1016/j.neuron.2017.07.010 · Cited by 799
The Role of Markers of Inflammation in Traumatic Brain Injury
Woodcock, T., & Morganti-Kossmann, M. C. (2013) · Frontiers in Neurology · doi:10.3389/fneur.2013.00018 · Cited by 712
Interleukin-6, a mental cytokine
Spooren, A., Kolmus, K., Laureys, G., Clinckers, R., De Keyser, J., Haegeman, G., & Gerlo, S. (2011) · Brain Research Reviews · doi:10.1016/j.brainresrev.2011.01.002 · Cited by 352
Helmy, A., Carpenter, K. L., Menon, D. K., Pickard, J. D., & Hutchinson, P. J. (2011) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2010.142 · Cited by 337
Preterm birth and sustained inflammation: consequences for the neonate
Humberg, A., Fortmann, I., Siller, B., Kopp, M. V., Herting, E., Göpel, W., Härtel, C., & German Neonatal Network, G. C. F. L. R. A. P. I. A. T. B. O. L. (. C. (2020) · Seminars in Immunopathology · doi:10.1007/s00281-020-00803-2 · Cited by 310
IL-6 regulation of synaptic function in the CNS
Gruol, D. L. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.10.023 · Cited by 254
Extracellular Vesicle Proteins and MicroRNAs as Biomarkers for Traumatic Brain Injury
Guedes, V. A., Devoto, C., Leete, J., Sass, D., Acott, J. D., Mithani, S., & Gill, J. M. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00663 · Cited by 85
“Other candidate biomarkers include markers of inflammatory responses and vascular injury (14, 24, 25), as well as circulating microRNAs (miRNAs), which are small non-coding RNAs with major roles in the regulation of gene expression (26, 27).”
BackgroundMolecular biomarkers of epileptogenesis
Pitkänen, A., & Lukasiuk, K. (2011) · Biomarkers in Medicine · doi:10.2217/bmm.11.67 · Cited by 40
Traumatic Brain Injury and Inflammation: Emerging Role of Innate and Adaptive Immunity
Dardiotis, E., Karanikas, V., Paterakis, K., Fountas, K., & M., G. (2012) · Brain Injury - Pathogenesis, Monitoring, Recovery and Management · doi:10.5772/27840 · Cited by 22
Metadata
- Authors
- Chiaretti, A., Antonelli, A., Mastrangelo, A., Pezzotti, P., Tortorolo, L., Tosi, F., & Genovese, O.
- Venue
- Journal of Neurotrauma
- Publisher
- SAGE Publications
- Published
- 2008-03
- Volume
- 25
- Issue
- 3
- Pages
- 225-234
- ISSN
- 0897-7151 (ISSN-L)
- 1557-9042
- OpenAlex
- W2016285277
- Cited by
- 108
- References
- 4
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.